SBI Healthcare Opportunities Fund Direct Plan-Growth
800000
1.24%
0.09%
0.15%
May 2025
JM Value Fund Direct Plan-Growth
179498
0.94%
0.02%
0.07%
May 2025
Nippon India Nifty Smallcap 250 Index Fund Direct - Growth
32676
0.08%
0.00%
0.00%
May 2025
Nippon India Nifty 500 Equal Weight Index Fund Direct-Growth
16605
0.23%
0.00%
0.03%
May 2025
SBI Nifty Smallcap 250 Index Fund Direct - Growth
20494
0.08%
0.00%
0.00%
May 2025
Motilal Oswal Nifty Smallcap 250 Index Fund Direct - Growth
13238
0.08%
0.00%
0.01%
May 2025
Axis Nifty 500 Index Fund Direct-Growth
414
0.01%
0.00%
0.00%
May 2025
HDFC Nifty Smallcap 250 Index Fund Direct-Growth
6818
0.08%
0.00%
0.00%
May 2025
Motilal Oswal Nifty 500 Index Fund Direct - Growth
3416
0.01%
0.00%
0.00%
May 2025
Edelweiss Nifty Smallcap 250 Index Fund Direct - Growth
1958
0.08%
0.00%
0.00%
May 2025
ICICI Prudential Nifty Smallcap 250 Index Fund Direct - Growth
7172
0.08%
0.00%
0.01%
May 2025
Groww Nifty Smallcap 250 Index Fund Direct - Growth
1609
0.08%
0.00%
0.01%
May 2025
Kotak Nifty Smallcap 250 Index Fund Direct-Growth
358
0.08%
0.00%
0.00%
May 2025
Navi Nifty 500 Multicap 50:25:25 Index Fund Direct-Growth
104
0.02%
0.00%
0.00%
May 2025
HDFC Nifty500 Multicap 50:25:25 Index Fund Direct-Growth
1708
0.02%
0.00%
0.00%
May 2025
SBI Nifty 500 Index Fund Direct-Growth
1255
0.01%
0.00%
0.00%
May 2025
ICICI Prudential Nifty 500 Index Fund Direct-Growth
36
0.01%
0.00%
0.00%
May 2025
Angel One Nifty Total Market Index Fund Direct - Growth
52
0.01%
0.00%
0.00%
May 2025
Mirae Asset Nifty Total Market Index Fund Direct-Growth
58
0.01%
0.00%
0.00%
May 2025
Bandhan BSE Healthcare Index Fund Direct-Growth
382
0.12%
0.01%
0.02%
May 2025
Bandhan Nifty Smallcap 250 Index Fund Direct-Growth
791
0.08%
0.00%
0.00%
May 2025
About Akums Drugs & Pharma
Akums Drugs and Pharmaceuticals Limited is an Indian pharmaceutical contract development and manufacturing organization (CDMO) established in 2004. The company offers a wide range of pharmaceutical products and services both domestically and internationally. Their operations include manufacturing of Active Pharmaceutical Ingredients (APIs), sale of branded pharmaceutical formulations, formulation research and development, regulatory dossier preparation and filing, and testing services. Akums has manufacturing units accredited by global regulatory agencies and specializes in various therapeutic areas. The company has expanded through acquisitions and establishment of new facilities over the years. It operates in three main segments: CDMO, API, and Branded and Generic formulations. Akums has manufactured over 4,000 commercialized formulations across more than 60 dosage forms.